Recruiting

C-CARBS

Sponsor:

UCLA

Code:

NCT07807280

Conditions

Type 1 Diabetes

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

C-Carbs Program

Study Details

Brief summary:

The goal of this randomized study is to learn whether a CGM-guided insulin dosing education program can help adults with diabetes improve how they dose mealtime insulin. The main question it aims to answer is:

1\. Does CGM-guided insulin dosing education improve insulin dosing behaviors and glycemic outcomes in adults with diabetes who do not routinely use carbohydrate counting?

Participants will be randomly assigned to either the C-CARBS intervention or usual care. Participants will complete study visits, questionnaires, and meal and insulin logs, and CGM data will be collected to evaluate changes in insulin dosing behaviors and glycemic outcomes.

Conditions

Type 1 Diabetes

Study ID

NCT07807280

Start date

Sep 30, 2026

Status verified date

Aug, 2026

Completion date

Nov 30, 2028

Anticipated

Primary completion date

May 31, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adults 18 years of age or older.
  • Diagnosis of diabetes for at least 1 year.
  • Currently using or willing to start using a continuous glucose monitor (CGM).
  • Currently using multiple daily insulin injections (MDI).
  • HbA1c ≥8% at screening/baseline.
  • Does not routinely use carbohydrate counting or demonstrates poor/inconsistent carbohydrate counting for mealtime insulin dosing.
  • Able and willing to participate in the study visits and intervention sessions.
  • Able to provide informed consent.

Exclusion Criteria:

  • Use of an insulin pump or automated insulin delivery system.
  • Significant medical, cognitive, or psychiatric condition that, in the investigator's judgment, would interfere with participation or completion of study procedures.

Limited life expectancy that would prevent completion of the study.

  • Pregnancy or plans to become pregnant during the study period.
  • Current participation in another interventional study that could affect diabetes management or study outcomes.
  • Inability/unwillingess to independently use a CGM device or administer insulin.
  • Any other condition that, in the investigator's judgment, would make participation inappropriate or interfere with the study's objectives.

Study Design

Enrollment

40 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

no intervention: Control

Participants will continue usual care and receive brief phone calls from research coordinator for breif diabetes education.

experimental: Intervention

Particpants will meet with a diabetes educator to complete the C-Carbs program.

Interventions

C-Carbs Program

The C-CARBS intervention is a patient-facing diabetes education program consisting of four weekly, one-hour sessions with a diabetes educator. The program teaches participants how to use continuous glucose monitoring (CGM) information, including current glucose levels and glucose trends, to guide mealtime insulin dosing. The intervention is designed to provide practical strategies for insulin dosing without relying solely on traditional carbohydrate counting. Participants will also practice applying CGM information to real-world meals and insulin dosing decisions.

Primary outcome measure

  • Change in HbA1C [ Time Frame: Baseline to Study Completion, 4 months ]

Central Contacts and Locations

Central contacts

Locations

University of California Los Angeles

Recruiting

Los Angeles, California, United States, 90095

Contacts

Principal Investigator:

Estelle Everett, MD, MHS

More Information

Sponsor

University of California, Los Angeles

Last update posted

Sep 8, 2026

Last verified

Aug, 2026

Keywords

  • Diabetes
  • Carbohydrate Counting
  • CGM

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of California, Los Angeles on 2026-09-08.